Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The Unnamed Molecular Glue Program is a preclinical drug discovery initiative by Evogene, developed in collaboration with an undisclosed biotechnology partner. The program leverages Evogene's ChemPass AI™ platform to identify and optimize small molecule molecular glues. These compounds are designed to modulate protein-protein interactions (PPIs) by either stabilizing or disrupting the interface between two proteins. Molecular glues typically function by inducing proximity between a target protein and another protein, such as an E3 ubiquitin ligase, to facilitate therapeutic outcomes like targeted protein degradation or functional modulation of previously 'undruggable' targets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Unnamed Molecular Glue Program (Evogene).